PRESS RELEASE published on 11/08/2024 at 07:00, 1 year ago LIGHTON announces the launch of its IPO on the Euronext Growth market in Paris. LightOn announces the launch of its IPO on the Euronext Growth market in Paris, offering a capital increase of around €10.4 million with subscription commitments from cornerstone investors. Subscription price: €10.35/share Businesses Paris IPO Euronext Growth LightOn
BRIEF published on 10/22/2024 at 07:35, 1 year 1 month ago LIGHTON validates its IPO on Euronext Growth Strategic Partnerships Generative AI Business Growth IPO Euronext Growth
PRESS RELEASE published on 10/22/2024 at 07:30, 1 year 1 month ago LIGHTON, a leading European player in generative AI for businesses, announces the approval of its registration document by the AMF as part of its planned IPO on Euronext Growth® Paris. LIGHTON, a leading European player in generative AI, receives AMF approval for IPO on Euronext Growth® Paris, marking the first step. Strategic partnerships with Orange Business & HPE for business development Strategic Partnerships Generative AI IPO AMF Approval LightOn
Published on 12/05/2025 at 02:35, 4 hours 33 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 8 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 3 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 8 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 38 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 17 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 43 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 53 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 58 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 13 hours 8 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 23 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 24 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025